

FOR IMMEDIATE RELEASE

LAUREATE PHARMA EXPANDS PROTEIN-PURIFICATION CAPACITY

PRINCETON, NJ – June 17, 2003 – Laureate Pharma L.P. announces the expansion of its purification capacity with the commissioning of a new automated chromatography system for GMP purification of protein products. The unit is specifically designed for biopharmaceutical purification applications, featuring polymeric, sanitary flowpaths and an array of detectors. In the coming months, the company anticipates installation and validation of an identically configured larger scale chromatography system to purify protein products produced in its 2,000-liter mammalian cell bioreactor. The combination of these units offers seamless scaling to support Laureate's bioreactor production operations. Laureate Pharma, a privately held contract manufacturing company, offers a full range of services to clients requiring development and GMP manufacture of monoclonal antibodies or other well characterized proteins for therapeutic use.

"Combined with our process development and manufacturing expertise, this automated, validated, and Part 11 compliant system offers our clients the confidence that their biopharmaceutical product will be purified accurately and consistently in compliance with cGMPs. Our team is looking forward to fully utilizing the new equipment to successfully meet purification requirements presented by our clients." said Bruce Weaver, Manager of Protein Purification at Laureate Pharma. Michiel E. Ultee, Ph.D., Sr. Director of Biopharmaceutical Development and Operations, adds, "The expansion of our purification capability is an important step in Laureate Pharma's mission to be a leader in the biopharmaceutical contract-services business. In addition to supporting the production needs of clients using our 200 and 2,000-liter bioreactors, we also foresee new opportunities for purification of feedstock from transgenic protein-production sources."

Laureate Pharma is a privately held contract manufacturing services company with headquarters in Princeton, NJ. Laureate Pharma's biopharmaceutical division, located in Princeton, NJ, provides a wide range of product development services from process design and development to full-scale cGMP production, purification and aseptic filling, as well as corresponding analytical services and regulatory support. The division is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Mammalian cells are grown in stirred-tank or hollow-fiber bioreactors for production of biopharmaceutical proteins, which are purified by state-of-the-art automated chromatography systems.

Laureate Pharma's sustained release technologies division, located in Totowa, NJ and focused on the manufacture of sustained release microparticle products, supplies development, formulation and filling services from clinical through commercial scale at its cGMP manufacturing facility. For more information on Laureate Pharma, contact the company directly at (609) 919-3400, by email at info@laureatepharma.com or visit www.laureatepharma.com.